3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
11
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
68
Skin Neoplasms
15
Neoplasm Metastasis
14
Lymphoma, T-Cell, Cutaneous
9
Carcinoma, Renal Cell
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Neoplasms
7
Lymphoma
7
Ovarian Neoplasms
6
Mycosis Fungoides
6
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
6
Uveal Melanoma
5
Uterine Cervical Neoplasms
5
Sezary Syndrome
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Sarcoma, Synovial
4
Pancreatic Neoplasms
4
Lung Neoplasms
4
Head and Neck Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Lymphoma, Non-Hodgkin
3
Interventions
pembrolizumab
4
Drug Therapy
3
Temozolomide
2
Radiation
2
Paclitaxel
2
Nivolumab
2
Cisplatin
2
Bevacizumab
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
selinexor
1
rovalpituzumab tesirine
1
regorafenib
1
pazopanib
1
niraparib
1
imetelstat
1
fludarabine
1
erythromycin propionate-N-acetylcysteinate
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dostarlimab
1
cobimetinib
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
bemcentinib
1
aflibercept
1
WP1066
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
fludarabine
×
Dermatologic
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled